Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata
Completed
University of California, San Francisco
N/A
2005-06-01
This is a single center, randomized, investigator-masked study to determine the efficacy and
safety of latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in
patients who have lost their eyelashes due to alopecia areata. These medications are
FDA-approved as eyedrops for patients with glaucoma who have been noted to grow longer,
darker, and thicker eyelashes with their use. In this study, patients will be asked to apply
these solutions to the affected eyelid margins of one eye with a sterile cotton-tipped
applicator once a day.
To compare the intraocular pressure effect and safety of the dorzolamide/timolol fixed
combination given twice daily versus bimatoprost given once every evening in patients with
open-angle glaucoma in patients insufficiently controlled on latanoprost monotherapy
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
